Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Ongoing Initiated Aug 19, 2026 (2 months ago)

Revcovi (elapegademase-lvlr)

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Failed Stability Specifications: Out of specification stability result for the protein concentration profile.

Cause type: Stability / shelf life

The product degraded or failed stability testing before its labeled expiry. Heat, moisture or time can break the drug down into degradants or reduce potency. All stability / shelf life recalls.

What was recalled

Revcovi (elapegademase-lvlr) Injection, 2.4mg/1.5mL (1.6 mg/mL), Single-Dose Vial, Rx Only, For Intramuscular Use Only, Mfd. by Chiesi USA, Inc., Cary, NC 27518, NDC 10122-502-01

Affected NDC 10122-0502-01

Compare with the code on your package — it is the most precise check available.

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Revcovi
elapegademase-lvlr
NDC 10122-0502
ELAPEGADEMASE 1.6 mg/mL Injection
Intramuscular
Chiesi USA, Inc. Rx
Recalling firm
Chiesi USA, Inc.
NDC code
10122-502-01
Origin
NC, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0838-2026 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm.

Other recalls by Chiesi USA, Inc.

All 2026 recalls
Class II · Moderate risk

ZYFLO CR (zileuton)

Failed Dissolution Specifications: Out of specification result for dissolution.

Terminated Dissolution failure Chiesi USA, Inc. NDC 10122-902-12 D-1341-2019

Other stability / shelf life recalls from 2026

All stability / shelf life recalls